C. R. Bard, Inc.

2015 Annual Report

Net Sales
(in millions of dollars)

3,323.6 3,416.0
Net Sales +9% +3%
3,049.5
(in millions of dollars) FINANCIAL HIGHLIGHTS
3,323.6 3,416.0
+9% +3%
3,049.5
Net Sales Operations as of and for the year ended December 31:
(in millions of dollars) (dollars in millions except per share data) 2015 2014 2013
13 14 15
3,323.6 3,416.0
Net sales $ 3,416.0 $ 3,323.6 $ 3,049.5
+9% +3%
3,049.5 Net income $ 135.4 $ 294.5 $ 689.8
Diluted earnings per share available
13 14 15
to common shareholders $ 1.77 $ 3.76 $ 8.39
Diluted earnings per share available
to common shareholders
excluding the items identified below $ 9.08 $ 8.40 $ 6.51
13 14 15 Cash dividends paid per share $ 0.92 $ 0.86 $ 0.82
Diluted Earnings Per
Share Available To Research and development expense $ 259.2 $ 302.0 $ 295.7
Common Shareholders1 Return on shareholders’ investment 8.3% 15.1% 34.4%
(in dollars)
Number of employees 14,900 13,900 13,000
Diluted Earnings Per
9.08
Share Available
8.40 To “Net sales in constant currency” and “diluted earnings per share available to common shareholders excluding the items identified
+8% 1
Common +29%
Shareholders below” (adjusted EPS) are non-GAAP financial measures. For a reconciliation of net sales in constant currency, see page II-5 in 
(in dollars) the accompanying Annual Report on Form 10-K for the year ended December 31, 2015 (Form 10-K).
6.51
Net Income and Adjusted Earnings Per Share Reconciliation
9.08
8.40
Diluted Earnings Per
+8% •D
 escribed below are certain items in each of 2015, 2014 and 2013 that affect the comparability of the company’s results of
+29%
Share Available To operations between periods.
Common
6.51 Shareholders 1

(in dollars) •F
 or the year ended December 31, 2015, the following items affected the comparability of results between periods: (i) net
charges of $31.7 million pre-tax for acquisition-related items including transaction costs, purchase accounting adjustments
13 14 15 and integration costs; (ii) a charge of $4.5 million pre-tax related to an asset impairment; (iii) charges of $595.1 million pre-tax
9.08 related to estimated costs for product liability matters (net of recoveries), which includes $15.1 million of litigation-related 
8.40
1 +8%
Excluding the items identified defense costs in connection with the District Court’s pre-trial orders that the company prepare 500 individual cases for trial
+29% (the “WHP Pre-Trial Orders”) and other litigation-related charges; (iv) a gain of $210.5 million pre-tax related to a patent
to the right
infringement litigation against W. L. Gore & Associates, Inc. (“Gore”); and (v) charges of $41.5 million pre-tax for restructuring
6.51
and productivity initiatives. The net effect of these items decreased net income by $480.4 million, or $6.28 diluted earnings
13 14 15 per share available to common shareholders. Amortization of intangible assets was $119.5 million pre-tax, which decreased
1
net income on an adjusted basis by $79.3 million, or $1.04 diluted earnings per share available to common shareholders.
Excluding the items identified
to the right •F
 or the year ended December 31, 2014, the following items affected the comparability of results between periods: (i) net
charges of $31.9 million pre-tax for acquisition-related items including purchased research and development, transaction
costs, purchase accounting adjustments and integration costs; (ii) a credit of $3.5 million pre-tax related to the excise tax 
paid on U.S. medical device sales in 2013 associated with an agreement reached with the IRS during 2014; (iii) a charge of
13 14 15 $6.2 million pre-tax related to an asset impairment; (iv) charges of $288.6 million pre-tax related to estimated costs for 
product liability matters (net of recoveries), which includes $30.1 million of litigation-related defense costs in connection 
Cash
1 Dividends
Excluding the items identified with the WHP Pre-Trial Orders; (v) charges of $11.8 million pre-tax for restructuring and productivity initiatives; (vi) a gain 
Paid
to the Per
right Share of $7.1 million pre-tax related to the sale of an equity investment; and (vii) a decrease of $10.9 million in the income tax 
(in dollars) provision associated with the completion of IRS examinations for the tax years 2008 through 2010. The net effect of these
items decreased net income by $291.5 million, or $3.72 diluted earnings per share available to common shareholders. 
Amortization of intangible assets was $108.8 million pre-tax, which decreased net income on an adjusted basis by $72.4 
Cash Dividends
.86 .92 million, or $0.92 diluted earnings per share available to common shareholders.
Paid +7%
.82Per Share
+5%
•F
 or the year ended December 31, 2013, the following items affected the comparability of results between periods: (i) charges
(in dollars)
of $50.3 million pre-tax for acquisition-related items including purchased research and development, transaction costs, 
purchase accounting adjustments and integration costs; (ii) charges of $12.3 million pre-tax related to asset impairments; 
.86 .92 (iii) a gain of $894.3 million pre-tax related to a patent infringement judgment against Gore; (iv) charges of $428.0 million
+7% pre-tax related to estimated costs for product liability matters (net of recoveries), and other litigation matters; (v) a gain of
Cash +5%
.82Dividends $213.0 million pre-tax related to the sale of the electrophysiology division; (vi) a charge of $22.5 million pre-tax related to a
Paid Per Share contribution to the C. R. Bard Foundation, Inc.; (vii) charges of $17.5 million pre-tax for divestiture-related costs; (viii) a 
(in dollars) reversal of $1.4 million pre-tax of restructuring costs; and (ix) a decrease of $2.2 million in the income tax provision 
associated with the remeasurement of an uncertain tax position as a result of a legal settlement. The net effect of these 
items increased net income by $214.9 million, or $2.61 diluted earnings per share available to common shareholders. 
13 14 15
.86 .92 Amortization of intangible assets was $89.5 million pre-tax, which decreased net income on an adjusted basis by $60.2 
+7% million, or $0.73 diluted earnings per share available to common shareholders.
.82 +5%
Important Information Regarding Forward-Looking Statements
This report may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995,
13 14 15 which are based on management’s current expectations, the accuracy of which is necessarily subject to risks and uncertainties.
These statements are not historical in nature and use words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” 
“forecast,” “plan,” “believe” and other words of similar meaning in connection with any discussion of future operating or 
financial performance. Many factors may cause actual results to differ materially from anticipated results including product 
developments, sales efforts, income tax matters, the outcomes of contingencies such as legal proceedings, and other economic,
business, competitive and regulatory factors. The company undertakes no obligation to update its forward-looking statements.
Please refer to “Risks and Uncertainties; Cautionary Statement Regarding Forward-Looking Information” in the company’s 2015
13 14 15 10-K for more detailed information about these and other factors that may cause actual results to differ materially from those
expressed or implied.
ADVANCING
LIVES AND THE
DELIVERY OF
HEALTH CARE™
C. R. Bard, Inc., is a leading multinational developer, manufacturer
and marketer of innovative, life-enhancing medical technologies
in the fields of vascular, urology, oncology and surgical specialties.
We market our products and services worldwide to hospitals,
individual health care professionals, extended-care facilities and
alternate-site facilities. We pioneered the development of single-use
medical products for hospital procedures, and we are committed
to pursuing technological innovations that offer superior clinical
benefits while helping to reduce overall health care costs.

C. R. Bard, Inc. 2015 Annual Report 1

 DEAR SHAREHOLDERS

John H. Weiland
President and
Chief Operating Officer

Timothy M. Ring
Chairman and
Chief Executive Officer

It has now been three full years since we first

outlined our strategic investment plan designed
to restore the revenue growth of our portfolio
to above-market rates while enhancing our
long-term prospects. Since then, we have been
focused on executing the plan and we are
pleased to report that 2015 was a year of high
performance and high achievement for Bard.

2 C. R. Bard, Inc. 2015 Annual Report

 While we’re pleased with the execution of the plan so far, we intend to continue focusing on shifting
the mix of our portfolio to faster growth by expanding in faster-growing geographies, investing in research
and development (R&D) in faster-growing product segments, and acquiring new growth platforms.

GLOBAL REACH
In November, we closed the acquisition of Medicon Inc. (“Medicon”), an organization we had previously
operated as a 50% owned joint venture with Kobayashi Pharmaceutical Co., Ltd., for over four decades
(see page 6). The Japanese health care market is the third-largest in the world, and we expect future
growth opportunities to be identified in market segments which are more clinically differentiated, such
as those served by Bard’s Crosser® CTO Recanalization Catheters, Lutonix® Drug Coated Balloons,
Lifestent® Vascular Stent and Progel® Pleural Air Leak Sealant. As a wholly owned subsidiary of Bard,
Medicon will be able to take a more focused approach to investment, product registration and product
launch strategies.
Elsewhere in the world, emerging markets represented about 10% of our total revenue at the end of
2015. We believe there is still significant room for growth as we continue to develop markets for our
peripherally-inserted central catheters (PICCs), hernia repair products, and other products where we can
provide strong value to customers and their patients. Our emphasis on adding value by solving clinical
problems while reducing costs across the spectrum of care resonates around the world in both emerging
and developed markets.

EXPANDING OUR OFFERINGS

In recent years, we have expanded beyond our more traditional product categories by investing in new,
high-growth areas that still allow us to leverage our core strengths. Examples of these categories include
targeted temperature management, biosurgery, drug-coated balloons and home care urological products.
After years of development and clinical research, we completed the first full year of selling the Lutonix®
Drug Coated Balloon in the United States, and, to date, the results have exceeded our expectations.
We are pursuing additional indications and variations on the platform that we anticipate will broaden its
application even further.
In 2015, we acquired Vascular Pathways, Inc., a developer and supplier of vascular access devices, and
began to sell the Accucath® Intravenous Catheter System, which, along with our PICCs and Powerglide®
Midline family, allows us to offer a comprehensive line of guidewire-assisted peripheral devices to a
broad spectrum of patients with vascular access needs. In January 2016, we acquired Liberator Medical
Holdings, Inc. (“Liberator”), a direct-to-consumer distributor of durable medical equipment. The
acquisition of Liberator enhances our access to the growing home care market, specifically for intermittent
self-catheterization products including our recently introduced Magic3® Go self-lubricating catheter and
Hydrosil® Rose intermittent catheter, which is designed specifically for female patients. We believe home

C. R. Bard, Inc. 2015 Annual Report 3

health will become increasingly important as the population ages and more health care takes place outside
of the hospital setting.
In the surgical category, we introduced the Phasix™ ST Fully Resorbable Synthetic Mesh, adding
another differentiated product to our complex abdominal wall portfolio that also includes the XenMatrix™
AB family of antibacterial-coated biological surgical grafts. We also rolled out the Optifix™ Absorbable
Fixation System and the Capsure® Permanent Fixation System in the highly competitive fixation space.
We received U.S. regulatory clearance for our Pinpoint™ GT Freehand Stereotactic System for vascular
access. This technology is offered on the new Site~Rite® 8 Ultrasound System, which launched in Europe in
2015 and in the United States early in 2016. The combination of Site~Rite® Ultrasound, Pinpoint™ GT Needle
Guidance and Sherlock 3CG® Diamond Catheter Tip Confirmation provides an integrated clinical solution
for vascular catheter placements.
In all, 38 of the 40 products that we launched in 2015 were the results of organic R&D efforts.

OUR CULTURE
As our business continues to evolve, our capabilities and culture must keep pace while remaining true to
our Core Values of Quality, Integrity, Service and Innovation.
The concept of sustainability is aligned with these values and is inseparable from our strategic
objectives. Last year, we issued our first Sustainability Report, which provides our stakeholders with
details of our current performance and efforts related to sustainability, including products, people and
the environment. You can read the report on our website at www.crbard.com/Social-Responsibility.html.
With employees in more than 30 countries, we have long believed that inclusion, diversity and cultural
appreciation serve as a catalyst for our strategic initiatives. In 2015, we took our commitment a step further
as we launched a Global Inclusion Leadership Council comprised of diverse, respected and influential
leaders representing each of Bard’s major functions, geographies and businesses. The Council will not only
raise awareness of inclusion across Bard, but it will be responsible for reviewing and sharing ideas and
partnering with their organization’s leadership teams to build, execute and measure inclusion plans.

MANAGEMENT AND THE BOARD OF DIRECTORS

We always appreciate the capable guidance and counsel of our experienced Board of Directors, which
grew by one member this year with the addition of Robert M. Davis, Executive Vice President and Chief
Financial Officer, Merck & Co., Inc. He serves on the Audit, Finance and Science & Technology Committees.
While there were no changes to our senior management team, we did realign certain senior roles in
order to facilitate our company growth plans and enhance the capabilities of our leaders. John P.
Groetelaars was promoted to Group President and added Bard Access Systems to his existing
responsibilities for Davol, China, Australia / New Zealand and Rest of Asia. Timothy P. Collins, Group
President, added Bard Medical Division to his existing responsibilities for Worldwide Operations,

4 C. R. Bard, Inc. 2015 Annual Report

Canada, Europe, Middle East and Africa, and South Africa. Jim C. Beasley, Group President, assumed
responsibility for Medicon and for driving the new market development process across Bard to
enable and accelerate our growth in new and developing markets; he continues to be responsible for
Latin America, Bard Peripheral Vascular and Lutonix. Christopher S. Holland, Senior Vice President and
Chief Financial Officer, assumed responsibility for Business Development, Corporate Marketing,
Reimbursement, Healthcare Economics and Strategy.

THE YEAR AHEAD

We have been pleased with the execution of our investment plan, but our focus remains firmly on the
future, sustaining the momentum we have built and looking to seize the significant growth opportunities
that remain in front of us.
We believe true success will be measured over the long term as our organic engine continues to drive
revenue growth and profitability. The potential for growth in emerging markets remains high, as we have
only begun to penetrate these markets with a subset of our broad product portfolio. As we pursue new
indications in our products and expanded market development, we hope to unlock even more growth
from new and existing technology platforms. Our efforts, both through organic growth and business
development, will continue to focus on improving outcomes and adding value to the global health
care market.
We thank our employees for their hard work and diligent execution, which have made our achievements
in 2015 possible. As always, we also want to thank you, our shareholders, for your continued support.

Sincerely,

Timothy M. Ring John H. Weiland

Chairman and President and
Chief Executive Officer Chief Operating Officer

March 2, 2016

C. R. Bard, Inc. 2015 Annual Report 5

 MOVING FORWARD –
TOGETHER
Bard is not a newcomer to Japan, the third-largest health care market in the world. For
over 40 years, Bard products were marketed to local clinicians by Medicon, a joint venture
between Bard and Kobayashi Pharmaceutical Co., Ltd. In November, Bard increased its
presence by taking full ownership of Medicon.
Over the years, Medicon has built a significant market share in a number of important
segments, including urological drainage, implantable ports and hernia repair. As the growth
opportunities in Japan evolve, the organization has built enhanced clinical and regulatory
capabilities and opened the Medicon Healthcare Science Center (MHSC) in Tokyo, a cutting-
edge training center where clinicians are introduced to products and techniques that help
them advance lives and the delivery of health care.
In December, Interventional Cardiologist Hiroshi Ando, MD, was at the MHSC to train his
peers on the use of the Crosser® CTO Recanalization Catheter, the first such device available
in Japan and an example of the innovative products that are expected to drive Bard’s future
growth there.
“Japanese physicians know how to cross Chronic Total Occlusion (CTO) lesions with a
guidewire,” says Dr. Ando. “However, there are many cases where we can cross the CTO but
can’t advance a therapeutic device—such as a balloon catheter—to the lesion.” Instead of
bypassing the blockage, the Crosser® Catheter oscillates at a high frequency to bore through
the occlusion. The clinician is then able to thread an angioplasty balloon to the site, flatten
the plaque buildup against the arterial wall, and place a vascular stent to restore and maintain
blood flow.
Dr. Ando is eager to share his experience and knowledge of phased patient selection,
crossing techniques and helpful tips with other physicians. “It is very important for physicians
to become familiar with a new system and technique before actually using it on patients,”
he says. “This training program is an important contributor to the effective launch of the
Crosser® Catheter System in Japan.”

MEDICON HEALTHCARE
SCIENCE CENTER
TOKYO, JAPAN

6 C. R. Bard, Inc. 2015 Annual Report

C. R. Bard, Inc. 2015 Annual Report 7
8 C. R. Bard, Inc. 2015 Annual Report
 DAVOL INC.
IRVINE, CALIFORNIA

SUCCESS
ALL AROUND
It would be hard to find someone who has experienced Bard more fully than Kim Williams.
Kim joined Bard Peripheral Vascular in 2008 as a Program Manager in Tempe, Arizona
before a promotion to Section Manager at the Glens Falls Operation in Queensbury, New York.
After Bard’s Davol division acquired a new product line, she moved to Irvine, California to
assume her current role as Plant Manager at the facility that produces Progel® Pleural Air
Leak Sealant.
In 2014, Kim experienced pain in her stomach while visiting her sister in Las Vegas for
a medical conference. Initially, she suspected it was just a reaction to a recent meal—until
she noticed a palpable bulge in her belly button. She flew home to California and went
straight to the emergency room, where she was diagnosed with an umbilical hernia.
Though it is a relatively common condition, the physician recommended she get surgery
as soon as possible.
Davol is one of the global leaders in hernia repair, so Kim was an unusually well-informed
health care consumer. The fact that her physician recommended Davol’s Ventralex®
hernia patch gave her an extra measure of confidence. “It’s great to know that I work for
the company that makes the exact product that was recommended for my procedure,”
she says.
Kim missed only a week of work, and, in a short time, she was back to her fitness
routine. More than a year later, she feels as healthy as ever. In fact, 2015 was a banner
year for Kim. She was named a winner of the Charles Russell Bard Award (see page 13),
and later was asked to co-lead Bard’s Global Inclusion Leadership Council, an important
initiative for the company.
She made it through that whirlwind of activity without giving her procedure a second
thought. “I trust our products, so I figured whatever is going in me, it has to be good!”

C. R. Bard, Inc. 2015 Annual Report 9

 A PARADIGM FOR
PICC PLACEMENT
Italy is not the largest health care market in Europe—Germany, France and the United
Kingdom have greater populations—but it is the leading market in Europe for peripherally-
inserted central catheters (PICCs). In fact, Italy’s health care providers place more PICCs
than all but a handful of countries in the world.
To understand why PICCs are so popular for patients with longer-term needs in Italian
hospitals, it is important to recognize the value they represent compared to traditional
intravenous therapy—a critical consideration in a country that has a sophisticated national
health care system but is faced with a challenging economic climate. “For 15 days of
traditional intravenous (IV) therapy, we estimate that the average number of needle sticks in
one patient would be around 20, including IV cannula placement and taking blood samples,”
says Fabio Conti, Nursing Coordinator at Fondazione Policlinico Tor Vergata (PTV), a
university medical center in Rome. “Placing a PICC in the same patient covers the same
therapeutic needs with a single device and a single insertion.” With fewer skin punctures,
there are fewer opportunities for insertion complications.
In many global markets, PICCs must be placed by physicians. At PTV, nurses have
been trained to place PICCs since 2003, and a full-time PICC team staffed by nurses was
established in 2008. Operative Units are empowered to reach out directly to the hospital’s
PICC team, which conducts an evaluation of the patient’s peripheral veins to determine
whether a PICC is indicated. The nurse then proceeds directly to the insertion, guided by
Bard’s Site~Rite® Ultrasound System.
In recent years, the PICC program at PTV has become a model for other hospitals in the
Lazio region of Italy. “Last year, we partnered with Bard to train 10 other local hospitals who
were starting up a PICC program,” says Conti. “Bard is one of the main partnerships for our
hospital and for our university.”

POLICLINICO TOR VERGATA

UNIVERSITY MEDICAL CENTER
ROME, ITALY

10 C. R. Bard, Inc. 2015 Annual Report

C. R. Bard, Inc. 2015 Annual Report 11
 845.0 830.0
+11% +0% -2% 928.3 970.3
755.9 +5%
808.584030 842.4 845.0 +12%
830.0
+11% +0% -2%
646.867224
808.584030 755.9

485.150418
646.867224

323.433612
485.150418

161.716806
323.433612

PRODUCT GROUP
Net Sales
REVIEW 0.000000
161.716806
10 11 12 13* 14** 15
0.000000 (in millions of dollars)
970.3 10 11 12 13* 14** 15
928.3 +5%
842.4 845.0 +12%
Net Sales 830.0
+11%
(in millions +0%
of dollars) -2%
755.9
Net Sales 970.3
VASCULAR
(in millions of dollars)
842.4 Key
928.3
+12%
+5%
UROLOGY 28%
845.0Products
830.0 Net Sales Key Products
970.3 +11% +0% -2%
928.3 +5%
(in millions of dollars)
+12% 755.9 Endovascular Basic Drainage
842.4 845.0
Net Sales 830.0 Net Sales 835.9 845.0 Total
+11%
(in millions +0%
of dollars) -2% Biopsy Devices 757.8
(in millions of dollars)
734.8
776.6 +8% +1% 28% Self
Intermittent NetCatheters
Sales
755.9 970.3 Valvuloplasty Devices +3% +2% Urinary Catheters and Trays
928.3 718.1 +2% 835.9 845.0
842.4 845.0 +12%
704.166779
830.0
+5% Peripheral Angioplasty Catheters
734.8
28%
757.8 776.6 +8% +1% Infection Control Foley Catheters
Total
+11% Drug-coated PTA Balloons +3% +2% Ureteral Catheters and Stents
+0% -2% 718.1 +2%
755.9 563.333423 Vena Cava Filters Net
Urine Collection Sales
Devices
704.166779
10 11 12 13*
Peripheral 14**Stents
Vascular 15 Total
422.500067 and Stent Grafts
28% Net Sales
Continence
Surgical Continence Products
563.333423
Grafts Fecal Incontinence Products
281.666711
10 11 Dialysis
12 Access
13* Grafts
14** 15 Continence Management Devices
422.500067 Total
140.833356
Peripheral Vascular Grafts Net Sales Urological Specialties
281.666711 Brachytherapy Services,
10 11 12 13* 14** 15 Seeds and Accessories
0.000000
10 11 12 13 14 15
140.833356
Net Sales Specialty Foley Catheters
3 0.000000 (in millions of dollars) Stone Management Devices
% 10 11 12 13* 14** 15 835.9 845.0 10 11 12 13 14 15 Catheter Stabilization
776.6 +8% +1%
Net Sales 734.8 757.8 +2%
Targeted Temperature
Five-Year Compound Growth Rate: 5.1% +2% +3% Five-Year Compound Growth Rate: 3.3% Management Products
718.1
(in millions of dollars)
70.3 Net Sales 28% 835.9 845.0 Net Sales
25%
+5% 776.6 +8% +1% (in millions of dollars)
734.8 757.8 +2%
(in millions of dollars)
2015 Net Sales Growth 2015 Net Sales Growth
845.0 +2% +3% Net Sales 936.9
835.9 718.1
Constant Total 910.9 Constant
776.6 +8% +1% (in millions of dollars) 857.1 +6% +3%
Vascular
Net Sales 734.8 757.8 Reported Currency Net Sales Urology 779.5 812.4 +6%Reported Currency Total
(in millions+2%
718.1
+3%
of dollars)
+2%
28% +8% +4% 910.9 936.9 25% Net Sales
Endovascular 6% 10%
780.750144 Basic 2% +3% 4%
724.8Drainage 812.4 857.1 +6%
835.9 845.0 +6%
+4% 25% -4% 2%
Grafts 779.5
776.6 -6% –
+8% +1% Continence
+8%
734.8 757.8 780.750144
624.600116
+2% Total 724.8 Total
Total +2% +3% 5% 9% Urological Specialties -4% 1%
718.1 Vascular Net Sales Net Sales
Catheter Stabilization -2% –
10 11 12 13 14 15
468.450087
624.600116
25% Total
* In November 2013, Bard sold its electrophysiology
312.300058 division to Boston Scientific,
Total Urology 1% 4%
Net Sales
468.450087
retaining only the guidewire and temporary pacing electrode product lines.
** In 2014, the company began receiving royalty payments from W. L. Gore & Associates, Inc.
156.150029 Total
15 312.300058
10 11 12 13 14 15
Net Sales
0.000000
10 11 12 13 14 15
156.150029
10 11 12 13 14 15 Sales
Net
0.000000 (in millions of dollars)

910.9 936.9 10 11 12 13 14 15
0 857.1 +6% +3%
% 10 11 12
ONCOLOGY 13 14 15 Sales
Net 812.4Products
779.5 Key +6% SURGICAL SPECIALTIES Key Products
(in millions+4%
+8%of dollars)
724.8
Net Sales Implantable Ports 910.9 936.9 Net Sales Soft Tissue Repair
845.0
(in millions of dollars)
812.4 25%
+6%
+6% +3%
857.1Inserted
Peripherally (in millions of dollars) 27%
Inguinal Hernia Repair Products
779.5 Central
+1% 910.9 936.9 +8% +4% Catheters (PICCs) Net Sales 555.1 572.3 Ventral Hernia Repair Products
857.1 +6% +3%
724.8 Dialysis Access Catheters (in millions of dollars)
+11% +3%
Net Sales 812.4 499.0 Complex HerniaTotal
Repair Products
779.5 +6% (Dialysis) Total
+4%
(in millions of dollars) 450.0 455.1 +10% 555.1 572.3 Breast27%
Reconstruction Products
+8% +4% +1% +3% Net Sales
Net Sales
Vascular Access Ultrasound
724.8 476.916808
910.9 936.9 25%
(Ultrasound)
434.6 499.0 +11% Surgical Fixation Devices
857.1 +3% 450.0 455.1 +10%
779.5 812.4 381.533446
+6%
+6%
434.6 +4% +1% 27% Performance Irrigation
Total
Laparoscopic Devices
+8% +4% 476.916808
724.8 Total Net Sales
and Accessories
286.150085
381.533446 10 11 12 13 14 Net
15Sales Total Biosurgical Products
190.766723
286.150085
27% Net Sales Surgical Hemostats
Surgical Sealants
10 11 12 13 14 15
95.383362
190.766723 Total
Net Sales
15 0.000000
10 11 12 13 14 15
95.383362
10 11 12 13 14 15 Sales
Net
0.000000 (in millions of dollars)
Five-Year Compound Growth Rate: 5.3% 572.3 10 11Compound
Five-Year 12 Growth
13 Rate: 15
14 5.7%
555.1
9 +3%
% 10 11 12 13 14 15
Net Sales 499.0 +11%
2015 Net Sales Growth 450.0
(in millions 455.1 +10%
of dollars) 2015 Net Sales Growth
434.6 +4% +1%

Net Sales Constant 555.1 572.3 Constant
Oncology
(in millions of dollars) Reported Currency +11% +3% Surgical Specialties Reported Currency 17%
36.9 27%
450.0 455.1 +10%
499.0
+3% Ports 555.1 572.3
-6% -3% Soft Tissue Repair 4% 8%
+11% +3%
434.6 +4% +1%
Net and Midlines 499.0 8%
PICCsSales 11% Performance Irrigation -30% -28%
Dialysis
450.0
(in millions 455.1 +10%
of dollars)
5% 9%
Total
Biosurgical Products 14% 14% 17%Total
434.6 +4% +1% 572.3 Net Sales Net Sales
Ultrasound 555.1
5% 8% +3% 27% Total Surgical 17%
3% 6%
499.0 +11%
450.0 455.1 +10% 3% 6%
Total Oncology
+4% +1% Total
434.6
10 11 12 13 14 Total
15 Net Sales
Net Sales 17% Total
Net Sales
10 11 12 13 14 15
Total
15
10 11 12 13 14 15 Net Sales

12 C. R. Bard, Inc. 2015 Annual Report

10 11 12 13 14 15
2015 CHARLES RUSSELL BARD AWARD RECIPIENTS

These employees were nominated by their colleagues for their exemplary performance and
commitment to Bard’s principles of Quality, Integrity, Service and Innovation. Each has also
demonstrated the highest of personal values through a dedication to community and family.

Front, L-R: Middle, L-R: Rear, L-R:

Susannah Smallwood-Brown Lucio Vallejo David Clerkin

Finance Manager Senior Mexican Controller Engineering Manager
EMEA Projects Bard Operations Center ClearStream Technologies Ltd.
Bard EMEA Reynosa, Mexico Enniscorthy, Ireland
Crawley, UK
Joe Urban Haoyu Gao
Kimberly Williams Director of Global Marketing Manager, Government Affairs
Senior Operations Manager Interventional Urology Bard China
Davol Inc. Bard Medical Division Beijing, China
Irvine, CA Covington, GA
Donna Petrarca
Muriel Desmarais Uta Rosseck Operations Manager
Administrative Assistant Senior Product Manager Global Distribution Center
Davol Inc. Stent Grafts Covington, GA
Warwick, RI Bard Peripheral Vascular
Karlsruhe, Germany Joshua G. McDonough
David Barcomb Associate Director
Planning & Purchasing Christopher L. Swank, Sr. BPV Supply Chain
Manager/Lutonix Plant Manager Bard Peripheral Vascular
Glens Falls Technology Center Bard Access Systems Tempe, AZ
Queensbury, NY Salt Lake City, UT
(2014 Winner) Lori A. Grace
Gerardo L. Rivera Principal Regulatory
Senior Director, Plant QA Affairs Specialist
Bard Puerto Rico and Delran Lutonix, Inc.
Humacao, PR New Hope, MN
Tyson Anderson
R&D Program Manager II
Bard Peripheral Vascular
Tempe, AZ

C. R. Bard, Inc. 2015 Annual Report 13

 BOARD OF DIRECTORS
Timothy M. Ring
Chairman and
Chief Executive Officer
C. R. Bard, Inc.
David M. Barrett, MD
Emeritus President and
Chief Executive Officer
The Lahey Clinic
Clinical Professor of Surgery
Dartmouth Medical School
Marc C. Breslawsky
Retired Chairman and
Chief Executive Officer
Imagistics International Inc.
Robert M. Davis
Executive Vice President
and Chief Financial Officer
Merck & Co., Inc.
Herbert L. Henkel
Retired Chairman and
Chief Executive Officer
Ingersoll-Rand Company
John C. Kelly
Retired Vice President
and Controller
Wyeth
14 C. R. Bard, Inc. 2015 Annual Report
David F. Melcher
President and
Chief Executive Officer
Aerospace Industries
Association
Gail K. Naughton, PhD
Chairman and
Chief Executive Officer
Histogen, Inc.
Tommy G. Thompson
Former U.S. Department
of Health & Human
Services Secretary
Former Governor of
Wisconsin
John H. Weiland
President and
Chief Operating Officer
C. R. Bard, Inc.
Anthony Welters
Executive Chairman of
BlackIvy Group LLC
Tony L. White
Retired Chairman, President
and Chief Executive Officer
Applied Biosystems, Inc.
CORPORATE LEADERSHIP TEAM
Timothy M. Ring*
Chairman and
Chief Executive Officer
John H. Weiland*
President and
Chief Operating Officer
Christopher S. Holland*
Senior Vice President and
Chief Financial Officer
Jim C. Beasley*
Group President
Timothy P. Collins*
Group President
John P. Groetelaars*
Group President
Sharon M. Luboff*
Group Vice President
John A. DeFord, PhD*
Senior Vice President
Science, Technology and
Clinical Affairs
* Denotes Executive Officer
Samrat S. Khichi* Scott T. Lowry
Senior Vice President, Vice President
General Counsel and Treasurer
and Secretary
Frank Lupisella Jr.*
Andrea J. Casper Vice President
Vice President and Controller
Regulatory Affairs
Patrick D. Roche
Patricia G. Christian* Vice President
Vice President Information
Quality, Regulatory Technology Solutions
and Medical Affairs
Richard C. Rosenzweig
Todd W. Garner Vice President, Law
Vice President and Assistant Secretary
Investor Relations
Gin Schulz
Betty D. Larson* Vice President
Vice President Quality Assurance
Human Resources
Brian J. Leddin
Vice President
Global Ethics and
Compliance Officer
C. R. Bard, Inc. 2015 Annual Report 15
 CORPORATE INFORMATION

CORPORATE OFFICES REGISTRAR AND TRANSFER AGENT

730 Central Avenue Computershare Trust Company, N.A.
Murray Hill, New Jersey 07974 Shareholder Relations
(908) 277-8000 211 Quality Circle, Suite 210
www.crbard.com College Station, TX 77845
(800) 446-2617
AUDITORS www.computershare.com/investor
KPMG LLP
51 John F. Kennedy Parkway Please direct inquiries regarding change of address,
Short Hills, New Jersey 07078-2778 lost certificates and other share transfer matters
to the above address.
ANNUAL MEETING
10:00 a.m., Wednesday, April 20, 2016 COMPUTERSHARE INVESTMENT PLAN
Wyndham Hamilton Park Hotel and Conference Center FOR SHAREHOLDERS
175 Park Avenue Registered shareholders and non-shareholders may
Florham Park, NJ 07932
220 purchase Bard common stock at any time with a low fee
structure compared with normal brokerage fees. Dividends
200
SHAREHOLDER INFORMATION may be reinvested in Bard common stock at no cost to the
Additional shareholder or investor information on Bard’s shareholder. The plan is a convenient and economical way
180
reports or filings with the SEC, Corporate Governance for shareholders to initiate and increase their investment in
160
Guidelines, Code of Ethics for Senior Financial Officers and Bard through the purchase of shares with voluntary cash
other governance materials are posted on Bard’s website at payments and/or all or part of their dividends. Cash
140
www.crbard.com. Shareholders may receive, without charge, payments may be made by mail or through automatic
120
printed copies of these documents by contacting our monthly deductions from their bank account.
corporate offices, attention:
100 For details or enrollment in the Computershare Investment
80 W. Garner
Todd Plan or for direct deposit of dividends, simply contact
Vice President – Investor Relations Computershare, which administers these programs for Bard.
(908) 277-8065 Please direct inquiries to:

COMPARISON OF FIVE-YEAR CUMULATIVE TOTAL RETURNS Computershare Investment Plan

The graph below compares the cumulative total shareholder for Shareholders of C. R. Bard, Inc.
return on Bard common stock for the last five years with Computershare Trust Company, N.A.
the cumulative total return on the S&P 500 Index and the 211 Quality Circle, Suite 210
S&P 500 Health Care Equipment Index over the same period. College Station, TX 77845
The graph assumes the investment of $100 in each of Bard (800) 446-2617
common stock, the S&P 500 Index and the S&P 500 Health www.computershare.com/investor
Care Equipment Index on December 31, 2009, and that all
dividends were reinvested. PROPOSED NEXT FOUR DIVIDEND DATES
$220
2016 Record Date Payment Date
$200

Second May 2 May 13

$180
Third July 18 July 29
$160 Fourth October 24 November 4
$140
2017
$120
First January 23 February 3
$100

$80

Dec10 Dec11 Dec12 Dec13 Dec14 Dec15

Bard, AccuCath, Advancing Lives and the Delivery of Health Care, CapSure, Crosser,
C.R. Bard, Inc. S&P 500 Index S&P 500 Health Care Equipment Index Hydrosil, LifeStent, Lutonix, Magic3, Medicon, Optifix, Phasix, Pinpoint, PowerGlide,
Progel, Sherlock 3CG, Site~Rite, Ventralex and XenMatrix are trademarks and/or
STOCK LISTED registered trademarks of C. R. Bard, Inc.
New York Stock Exchange (NYSE)
Symbol: BCR All other trademarks are the property of their respective owners.

SUSTAINABILITY
Read our Sustainability Report at
www.crbard.com/Social-Responsibility.html © 2016 C. R. Bard, Inc. All Rights Reserved.

16 C. R. Bard, Inc. 2015 Annual Report

C. R. Bard, Inc.

730 Central Avenue

Murray Hill, New Jersey 07974
www.crbard.com